Device-detected atrial high-rate episodes without prior AF

Implanted pacemakers, defibrillators and cardiac resynchronisation devices can identify rapid atrial activity long before a patient reports palpitations or receives a conventional diagnosis of atrial fibrillation (AF). These recordings are commonly described as atrial high-rate episodes (AHREs), subclinical AF or device-detected atrial tachyarrhythmias. They create a clinically important grey area: the rhythm may be genuine, but its duration, burden and relationship with stroke risk are not always straightforward.

For clinicians in Australia, interpretation must connect device data with the patient’s overall vascular risk, bleeding risk and ability to access follow-up. A device alert received by a clinic in Sydney, Melbourne or Brisbane may lead to a very different practical pathway from one generated in a rural or remote service. The Journal of Arrhythmia provides an open-access setting for reviewing evolving evidence in electrophysiology, pacing and stroke prevention.

What an atrial high-rate episode represents

An AHRE is an episode of atrial activity above a programmed rate threshold, often around 175–180 beats per minute, detected by an implanted device. Many systems require the rhythm to continue for several minutes before storing an episode, reducing alerts caused by brief artefacts. Definitions vary between studies and manufacturers, so an episode labelled “AHRE” should not automatically be treated as electrocardiographically confirmed AF.

Stored electrograms are essential. Oversensing, far-field R waves, lead problems, myopotential interference and atrial tachycardia can all resemble AF. A clinician should inspect the available electrogram, assess the regularity of atrial activity and, where appropriate, obtain a 12-lead ECG, ambulatory monitor or additional device interrogation. A short, irregular atrial episode with convincing electrogram evidence carries more clinical meaning than an isolated alert without a readable tracing.

The term “subclinical AF” is often used when the device recording has features consistent with AF but the patient has no symptoms and no previous clinical diagnosis. The distinction matters because device surveillance detects a broader range of atrial tachyarrhythmias than routine pulse checks or intermittent ECGs. Some patients experience episodes during sleep, after exercise or around periods of illness without noticing them. An everyday habit such as checking a smartwatch may provide a useful prompt, but consumer wearables do not replace confirmation from a medical-grade ECG or implanted-device electrogram.

Why duration and burden matter

Stroke risk appears to rise with longer and more frequent atrial arrhythmia, but there is no single duration that converts every AHRE into an indication for anticoagulation. Very brief episodes may be artefacts or markers of atrial vulnerability. Episodes lasting several hours, or recurring over days, suggest a greater arrhythmic substrate and deserve a more urgent assessment of thromboembolic risk.

The relationship between an episode and a stroke is also imperfect. A cerebral event may occur when no AHRE is recorded, while an AHRE may be detected days or weeks before or after the event. Hypertension, age, diabetes, heart failure, prior stroke or transient ischaemic attack, vascular disease and other markers of atrial cardiomyopathy can therefore be as important as the episode duration itself. The CHA₂DS₂-VASc score remains familiar in practice, although clinicians should apply the current local guideline and consider sex, age and comorbidities in context.

ASSERT showed that device-detected atrial tachyarrhythmias were associated with a higher risk of stroke and systemic embolism, particularly when episodes exceeded 24 hours. More recent randomised evidence has sharpened the discussion. ARTESiA found that apixaban reduced stroke or systemic embolism compared with aspirin in patients with device-detected subclinical AF lasting six minutes to 24 hours, while increasing major bleeding. NOAH-AFNET 6 did not show a clear net benefit from routine edoxaban in a related population and also raised concern about bleeding. These results support individualised decisions rather than a duration-only rule.

A practical assessment after device notification

When an AHRE is reported, the first step is to verify the rhythm and determine whether clinical AF has already been documented elsewhere. Review previous ECGs, emergency presentations, hospital discharge summaries, Holter reports and symptoms such as palpitations, exertional breathlessness, fatigue or transient neurological disturbance. A patient who has a diagnostic ECG showing AF should generally be managed under the clinical AF pathway, even if the implanted device detected the episode incidentally.

The next step is to assess reversible or modifiable contributors. Blood pressure, thyroid function, alcohol intake, sleep apnoea symptoms, obesity, diabetes and heart failure status can influence atrial arrhythmia. Australians may describe alcohol use in terms of weekend drinks, sporting events or regular social gatherings, and these patterns can be clinically relevant without being the sole explanation. Smoking cessation, weight management, treatment of hypertension and review of obstructive sleep apnoea may reduce future arrhythmia burden and improve cardiovascular health.

Device programming and follow-up also deserve attention. An electrophysiology or pacing service can review detection thresholds, stored electrograms, atrial lead performance and cumulative burden. Remote monitoring is increasingly used across Australian public and private hospitals, yet access can vary between metropolitan centres and regional services. A patient living outside Adelaide, Perth or Canberra may need coordinated telehealth review, local ECG access and a clear escalation plan rather than repeated long-distance travel.

Deciding about anticoagulation

Anticoagulation should be considered through shared clinical judgement. A patient with a brief, isolated AHRE, low thromboembolic risk and substantial bleeding concerns may reasonably undergo closer surveillance rather than immediate treatment. A patient with prolonged or recurrent episodes, previous stroke, advanced age, hypertension, diabetes or heart failure may have a stronger case for an oral anticoagulant, even when the rhythm has not produced symptoms.

The discussion should cover both absolute benefits and harms. Direct oral anticoagulants such as apixaban and rivaroxaban are widely used in Australia, while warfarin remains important for selected indications, including some patients with mechanical valves or significant mitral stenosis. Eligibility, prescribing rules and subsidy arrangements under the Pharmaceutical Benefits Scheme can affect affordability and continuity. A medication that is clinically suitable but difficult to obtain or manage will not deliver its intended protection.

Bleeding risk should be investigated rather than used as a reason to withhold treatment automatically. Review previous gastrointestinal bleeding, anaemia, renal function, falls, interacting medicines and regular use of aspirin or non-steroidal anti-inflammatory drugs. Shared decision-making should explain that anticoagulants reduce embolic risk but do not eliminate it, and that bleeding precautions, renal monitoring and adherence are part of treatment. In Australia, prescribing must also align with Therapeutic Goods Administration-approved indications and relevant professional guidance, while the patient’s privacy and remote-monitoring information are protected within the broader requirements of the Privacy Act 1988 and health-service policies.

Follow-up, prevention and research priorities

Patients with AHREs need a follow-up plan that states who will review the tracing, when the next device interrogation will occur and what symptoms require urgent assessment. Sudden weakness, facial droop, speech difficulty or visual loss should prompt emergency action for possible stroke. Sustained palpitations, syncope, chest pain or worsening breathlessness may indicate a separate urgent problem, even if the device episode itself was short.

Monitoring strategies can include remote device transmissions, periodic ECGs, ambulatory monitoring and review of atrial burden over time. A patient should know whether an alert is reviewed on the same day, during business hours or at a scheduled clinic appointment. This is particularly important for people using private cardiology services in Melbourne or Sydney as well as those receiving care through a public hospital network in regional Queensland or Western Australia.

Research is continuing into whether AHREs are a direct cause of embolism, a marker of atrial disease or both. Future tools may combine episode duration with atrial size, fibrosis, biomarkers, imaging, ventricular function and machine-learning analysis of electrograms. Trials comparing anticoagulation strategies, rhythm surveillance and integrated risk models should help refine treatment thresholds. Clinicians can keep pace by reviewing the latest arrhythmia research, including original studies, guidelines and educational reviews relevant to implanted devices and stroke prevention.

For now, a measured approach is safest: confirm the rhythm, quantify its duration and burden, assess the patient’s vascular and bleeding risks, address modifiable factors, and document a clear follow-up pathway. Australian electrophysiology teams, device clinics and general practitioners can work together to ensure that an incidental device notification becomes meaningful preventive care rather than an isolated technical alert.

Stay informed through current evidence in cardiac electrophysiology, use device recordings alongside clinical judgement, and direct questions about submissions, educational material or journal content to the editorial contact team.